{"id":49610,"date":"2025-12-01T15:42:32","date_gmt":"2025-12-01T07:42:32","guid":{"rendered":"https:\/\/flcube.com\/?p=49610"},"modified":"2025-12-01T15:42:33","modified_gmt":"2025-12-01T07:42:33","slug":"provivas-ptx-912-pd-1-il-2-fusion-gets-usd-30m-series-a-boost","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49610","title":{"rendered":"Proviva&#8217;s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost"},"content":{"rendered":"\n<p><strong>Proviva Therapeutics<\/strong> announced the completion of a <strong>Series A+ financing round<\/strong>, raising <strong>over USD\u202f30\u202fmillion<\/strong> led by <strong>OrbiMed<\/strong>, with participation from <strong>Hankang Capital, Sequoia China, and a globally renowned corporate venture fund<\/strong>. Proceeds will accelerate global clinical development of <strong>PTX\u2011912<\/strong>, a first\u2011in\u2011class PD\u20111\/IL\u20112 fusion protein, and advance several preclinical pipelines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-corporate-milestone\">Corporate Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Proviva Therapeutics<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Series A+<\/td><\/tr><tr><td><strong>Amount<\/strong><\/td><td>Over USD\u202f30\u202fmillion<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>OrbiMed<\/td><\/tr><tr><td><strong>Co\u2011Investors<\/strong><\/td><td>Hankang Capital, Sequoia China, Corporate Venture Fund<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Accelerate PTX\u2011912 global clinical development; advance preclinical pipelines<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>Not disclosed (post\u2011Series A+)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-ptx-912\">Drug Profile \u2013 PTX\u2011912<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> First\u2011in\u2011class fusion protein combining <strong>PD\u20111 antibody<\/strong> with <strong>IL\u20112 prodrug<\/strong><\/li>\n\n\n\n<li><strong>Dual Action:<\/strong> <strong>PD\u20111 blockade<\/strong> plus <strong>TME\u2011selective IL\u20112 signaling activation<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Designed to <strong>enhance anti\u2011tumor immune response<\/strong> while <strong>reducing severe systemic toxicity<\/strong> associated with IL\u20112 drugs<\/li>\n\n\n\n<li><strong>Current Status:<\/strong> Phase\u202fI dose\u2011escalation trial; preliminary data show <strong>good safety\/tolerability<\/strong> and <strong>confirmed Partial Response (cPR)<\/strong> in <strong>NSCLC<\/strong> patients<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform\">Technology Platform<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>PD\u20111 Blockade<\/strong><\/td><td>Releases immune brakes on T\u2011cells<\/td><\/tr><tr><td><strong>IL\u20112 Prodrug<\/strong><\/td><td>Activates IL\u20112 pathway selectively in tumor microenvironment<\/td><\/tr><tr><td><strong>Toxicity Reduction<\/strong><\/td><td>Minimizes systemic IL\u20112 exposure vs. traditional IL\u20112 therapy<\/td><\/tr><tr><td><strong>Clinical Data<\/strong><\/td><td>cPR observed in NSCLC; dose escalation ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Oncology Market<\/strong><\/td><td>$250\u202fbillion (2024)<\/td><\/tr><tr><td><strong>PD\u20111\/PD\u2011L1 Market<\/strong><\/td><td>$35\u202fbillion (2024)<\/td><\/tr><tr><td><strong>IL\u20112 Therapy Market<\/strong><\/td><td>$500\u202fmillion (niche due to toxicity)<\/td><\/tr><tr><td><strong>Combination Therapy Growth<\/strong><\/td><td>15% CAGR (2024\u20112030)<\/td><\/tr><tr><td><strong>Peak Sales Potential (PTX\u2011912)<\/strong><\/td><td><strong>$800\u202fmillion\u20111.2\u202fbillion<\/strong> if approved across solid tumors<\/td><\/tr><tr><td><strong>Competition:<\/strong> No approved PD\u20111\/IL\u20112 fusions globally; <strong>BMS, Roche<\/strong> exploring similar concepts pre\u2011clinically<\/td><td><\/td><\/tr><tr><td><strong>Next Catalyst:<\/strong> Phase\u202fIb expansion cohort data expected <strong>Q3\u202f2026<\/strong><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Proviva\u2019s financing utilization, PTX\u2011912 development, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, competitive dynamics, and regulatory approvals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD\u202f30\u202fmillion led&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49615,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,20,1417],"class_list":["post-49610","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-finance","tag-proviva-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Proviva&#039;s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD\u202f30\u202fmillion led by OrbiMed, with participation from Hankang Capital, Sequoia China, and a globally renowned corporate venture fund. Proceeds will accelerate global clinical development of PTX\u2011912, a first\u2011in\u2011class PD\u20111\/IL\u20112 fusion protein, and advance several preclinical pipelines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49610\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Proviva&#039;s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost\" \/>\n<meta property=\"og:description\" content=\"Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD\u202f30\u202fmillion led by OrbiMed, with participation from Hankang Capital, Sequoia China, and a globally renowned corporate venture fund. Proceeds will accelerate global clinical development of PTX\u2011912, a first\u2011in\u2011class PD\u20111\/IL\u20112 fusion protein, and advance several preclinical pipelines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49610\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-01T07:42:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T07:42:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Proviva&#8217;s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost\",\"datePublished\":\"2025-12-01T07:42:32+00:00\",\"dateModified\":\"2025-12-01T07:42:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610\"},\"wordCount\":312,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0101.webp\",\"keywords\":[\"Cancer\",\"Finance\",\"Proviva Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49610#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49610\",\"name\":\"Proviva's PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0101.webp\",\"datePublished\":\"2025-12-01T07:42:32+00:00\",\"dateModified\":\"2025-12-01T07:42:33+00:00\",\"description\":\"Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD\u202f30\u202fmillion led by OrbiMed, with participation from Hankang Capital, Sequoia China, and a globally renowned corporate venture fund. Proceeds will accelerate global clinical development of PTX\u2011912, a first\u2011in\u2011class PD\u20111\\\/IL\u20112 fusion protein, and advance several preclinical pipelines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49610\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Proviva's PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49610#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Proviva&#8217;s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Proviva's PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost - Insight, China&#039;s Pharmaceutical Industry","description":"Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD\u202f30\u202fmillion led by OrbiMed, with participation from Hankang Capital, Sequoia China, and a globally renowned corporate venture fund. Proceeds will accelerate global clinical development of PTX\u2011912, a first\u2011in\u2011class PD\u20111\/IL\u20112 fusion protein, and advance several preclinical pipelines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49610","og_locale":"en_US","og_type":"article","og_title":"Proviva's PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost","og_description":"Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD\u202f30\u202fmillion led by OrbiMed, with participation from Hankang Capital, Sequoia China, and a globally renowned corporate venture fund. Proceeds will accelerate global clinical development of PTX\u2011912, a first\u2011in\u2011class PD\u20111\/IL\u20112 fusion protein, and advance several preclinical pipelines.","og_url":"https:\/\/flcube.com\/?p=49610","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-01T07:42:32+00:00","article_modified_time":"2025-12-01T07:42:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49610#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49610"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Proviva&#8217;s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost","datePublished":"2025-12-01T07:42:32+00:00","dateModified":"2025-12-01T07:42:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49610"},"wordCount":312,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49610#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101.webp","keywords":["Cancer","Finance","Proviva Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49610#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49610","url":"https:\/\/flcube.com\/?p=49610","name":"Proviva's PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49610#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49610#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101.webp","datePublished":"2025-12-01T07:42:32+00:00","dateModified":"2025-12-01T07:42:33+00:00","description":"Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD\u202f30\u202fmillion led by OrbiMed, with participation from Hankang Capital, Sequoia China, and a globally renowned corporate venture fund. Proceeds will accelerate global clinical development of PTX\u2011912, a first\u2011in\u2011class PD\u20111\/IL\u20112 fusion protein, and advance several preclinical pipelines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49610#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49610"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49610#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101.webp","width":1080,"height":608,"caption":"Proviva's PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49610#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Proviva&#8217;s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49610"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49610\/revisions"}],"predecessor-version":[{"id":49616,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49610\/revisions\/49616"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49615"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}